| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 16 | 2025 | 547 | 3.840 |
Why?
|
| Immunotherapy, Adoptive | 15 | 2026 | 949 | 2.860 |
Why?
|
| Liver Neoplasms | 23 | 2026 | 1366 | 2.850 |
Why?
|
| Interleukin-15 | 6 | 2026 | 103 | 2.750 |
Why?
|
| Hepatoblastoma | 13 | 2026 | 203 | 2.300 |
Why?
|
| Natural Killer T-Cells | 7 | 2025 | 90 | 2.080 |
Why?
|
| Glypicans | 4 | 2024 | 36 | 1.990 |
Why?
|
| Carcinoma, Hepatocellular | 12 | 2026 | 976 | 1.950 |
Why?
|
| T-Lymphocytes | 10 | 2026 | 1710 | 1.720 |
Why?
|
| Receptors, Antigen, T-Cell | 7 | 2025 | 499 | 1.350 |
Why?
|
| Bone Neoplasms | 2 | 2023 | 469 | 1.030 |
Why?
|
| Gangliosides | 5 | 2025 | 71 | 0.990 |
Why?
|
| Alkaline Phosphatase | 1 | 2026 | 94 | 0.950 |
Why?
|
| Synthetic Biology | 1 | 2025 | 14 | 0.890 |
Why?
|
| Receptors, Antigen | 3 | 2016 | 33 | 0.860 |
Why?
|
| Neoplasms | 6 | 2025 | 2980 | 0.850 |
Why?
|
| Genetic Engineering | 1 | 2025 | 161 | 0.820 |
Why?
|
| Immunotherapy | 4 | 2017 | 759 | 0.730 |
Why?
|
| Osteosarcoma | 1 | 2023 | 274 | 0.660 |
Why?
|
| DNA | 1 | 2025 | 1400 | 0.600 |
Why?
|
| CD28 Antigens | 2 | 2016 | 76 | 0.590 |
Why?
|
| Interleukins | 1 | 2020 | 121 | 0.580 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 105 | 0.530 |
Why?
|
| Child | 29 | 2026 | 26175 | 0.520 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2016 | 25 | 0.490 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 143 | 0.480 |
Why?
|
| Periodicals as Topic | 1 | 2018 | 182 | 0.470 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 547 | 0.470 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 126 | 0.470 |
Why?
|
| Lymphoma, B-Cell | 2 | 2016 | 145 | 0.460 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 690 | 0.460 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 2023 | 271 | 0.450 |
Why?
|
| Ambulatory Care | 1 | 2018 | 401 | 0.450 |
Why?
|
| Child, Preschool | 21 | 2026 | 15006 | 0.440 |
Why?
|
| Health Care Costs | 1 | 2018 | 406 | 0.440 |
Why?
|
| Humans | 50 | 2026 | 130123 | 0.430 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 393 | 0.420 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 980 | 0.400 |
Why?
|
| Cancer Vaccines | 1 | 2014 | 188 | 0.380 |
Why?
|
| Lymphocyte Activation | 5 | 2020 | 634 | 0.370 |
Why?
|
| Adolescent | 20 | 2026 | 20800 | 0.360 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 1332 | 0.360 |
Why?
|
| Liver Transplantation | 7 | 2025 | 1129 | 0.350 |
Why?
|
| Embolization, Therapeutic | 2 | 2025 | 224 | 0.340 |
Why?
|
| Cell Proliferation | 5 | 2026 | 2463 | 0.340 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2024 | 1000 | 0.320 |
Why?
|
| Hematologic Neoplasms | 2 | 2025 | 314 | 0.310 |
Why?
|
| Animals | 13 | 2026 | 33697 | 0.300 |
Why?
|
| Male | 26 | 2026 | 64386 | 0.300 |
Why?
|
| Mice | 11 | 2024 | 18172 | 0.290 |
Why?
|
| Incidence | 4 | 2024 | 3314 | 0.280 |
Why?
|
| Female | 24 | 2026 | 70274 | 0.270 |
Why?
|
| Infant | 14 | 2026 | 13275 | 0.260 |
Why?
|
| Single-Chain Antibodies | 1 | 2026 | 42 | 0.240 |
Why?
|
| Survival Rate | 4 | 2024 | 2112 | 0.240 |
Why?
|
| Yttrium Radioisotopes | 2 | 2025 | 22 | 0.240 |
Why?
|
| Mice, Inbred NOD | 4 | 2020 | 300 | 0.230 |
Why?
|
| Cell Line, Tumor | 5 | 2026 | 3714 | 0.230 |
Why?
|
| Neutropenia | 3 | 2024 | 210 | 0.220 |
Why?
|
| Mice, SCID | 4 | 2020 | 585 | 0.220 |
Why?
|
| Young Adult | 8 | 2024 | 9986 | 0.220 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2024 | 22 | 0.210 |
Why?
|
| Prognosis | 8 | 2025 | 4848 | 0.210 |
Why?
|
| Mutagenesis, Insertional | 1 | 2025 | 150 | 0.210 |
Why?
|
| Adenosine Deaminase | 1 | 2024 | 89 | 0.210 |
Why?
|
| Mutagenesis | 1 | 2025 | 325 | 0.200 |
Why?
|
| SEER Program | 2 | 2022 | 213 | 0.200 |
Why?
|
| Vincristine | 2 | 2024 | 188 | 0.200 |
Why?
|
| Interleukin-6 | 1 | 2024 | 410 | 0.190 |
Why?
|
| Sequence Deletion | 1 | 2025 | 517 | 0.190 |
Why?
|
| RNA, Long Noncoding | 1 | 2025 | 219 | 0.190 |
Why?
|
| Cohort Studies | 2 | 2024 | 5041 | 0.180 |
Why?
|
| Lymphocyte Depletion | 2 | 2024 | 124 | 0.180 |
Why?
|
| Cytokines | 3 | 2017 | 1342 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 1 | 2025 | 1454 | 0.170 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 975 | 0.170 |
Why?
|
| Lymphoma | 1 | 2024 | 327 | 0.170 |
Why?
|
| Leukemia | 1 | 2024 | 375 | 0.170 |
Why?
|
| Mutation | 3 | 2026 | 6069 | 0.170 |
Why?
|
| Treatment Outcome | 8 | 2025 | 12840 | 0.160 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 1121 | 0.160 |
Why?
|
| Vidarabine | 1 | 2020 | 91 | 0.160 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2020 | 27 | 0.160 |
Why?
|
| United States | 4 | 2024 | 11881 | 0.160 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 55 | 0.160 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2020 | 91 | 0.160 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2020 | 100 | 0.150 |
Why?
|
| Immunity | 1 | 2020 | 179 | 0.150 |
Why?
|
| Aicardi Syndrome | 1 | 2019 | 17 | 0.150 |
Why?
|
| Automobiles | 1 | 2019 | 4 | 0.150 |
Why?
|
| Agenesis of Corpus Callosum | 1 | 2019 | 49 | 0.150 |
Why?
|
| Middle Aged | 4 | 2024 | 28325 | 0.150 |
Why?
|
| Vocal Cord Paralysis | 1 | 2020 | 66 | 0.150 |
Why?
|
| Macrophages | 2 | 2014 | 660 | 0.150 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 16 | 0.140 |
Why?
|
| Cell Differentiation | 1 | 2026 | 1910 | 0.140 |
Why?
|
| Transplantation Conditioning | 2 | 2017 | 327 | 0.140 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 426 | 0.140 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 1391 | 0.140 |
Why?
|
| DNA-Binding Proteins | 1 | 2026 | 1933 | 0.140 |
Why?
|
| Survival Analysis | 2 | 2018 | 1481 | 0.140 |
Why?
|
| Follow-Up Studies | 6 | 2025 | 5161 | 0.140 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2018 | 20 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2026 | 1586 | 0.130 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 302 | 0.130 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2018 | 103 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2017 | 145 | 0.130 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 118 | 0.130 |
Why?
|
| Registries | 1 | 2024 | 1609 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2018 | 361 | 0.130 |
Why?
|
| Bacterial Infections | 1 | 2020 | 328 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2017 | 137 | 0.130 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2017 | 41 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2017 | 60 | 0.130 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 1214 | 0.120 |
Why?
|
| Transcription Factors | 1 | 2026 | 2404 | 0.120 |
Why?
|
| Myeloid Cells | 1 | 2017 | 112 | 0.120 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2018 | 215 | 0.120 |
Why?
|
| L-Selectin | 1 | 2016 | 18 | 0.120 |
Why?
|
| Acetylation | 1 | 2017 | 191 | 0.120 |
Why?
|
| Cholangiocarcinoma | 1 | 2018 | 125 | 0.120 |
Why?
|
| Apoptosis | 2 | 2020 | 1830 | 0.120 |
Why?
|
| Adult | 6 | 2024 | 31032 | 0.120 |
Why?
|
| Transduction, Genetic | 2 | 2014 | 277 | 0.120 |
Why?
|
| Infant, Newborn | 4 | 2024 | 8550 | 0.120 |
Why?
|
| Bile Duct Neoplasms | 1 | 2018 | 134 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 1 | 2017 | 142 | 0.120 |
Why?
|
| Cell Polarity | 1 | 2016 | 118 | 0.120 |
Why?
|
| Translocation, Genetic | 1 | 2017 | 343 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 816 | 0.110 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 92 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2025 | 1802 | 0.110 |
Why?
|
| Antigens, CD19 | 1 | 2016 | 190 | 0.110 |
Why?
|
| Retrospective Studies | 9 | 2025 | 17547 | 0.110 |
Why?
|
| Liver Diseases | 1 | 2019 | 378 | 0.110 |
Why?
|
| Brain Diseases | 1 | 2018 | 298 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 679 | 0.110 |
Why?
|
| 4-1BB Ligand | 1 | 2014 | 11 | 0.110 |
Why?
|
| Disease Management | 1 | 2018 | 555 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 383 | 0.110 |
Why?
|
| Antigens, CD1d | 1 | 2014 | 20 | 0.110 |
Why?
|
| Genes, T-Cell Receptor | 1 | 2013 | 2 | 0.100 |
Why?
|
| Retroviridae | 1 | 2014 | 182 | 0.100 |
Why?
|
| Abnormalities, Multiple | 1 | 2019 | 964 | 0.100 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2016 | 510 | 0.100 |
Why?
|
| Health Personnel | 1 | 2018 | 537 | 0.100 |
Why?
|
| B7-H1 Antigen | 2 | 2026 | 133 | 0.100 |
Why?
|
| Sarcoma | 1 | 2016 | 218 | 0.100 |
Why?
|
| Phenotype | 2 | 2026 | 4464 | 0.100 |
Why?
|
| Liver | 2 | 2019 | 1787 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 716 | 0.090 |
Why?
|
| Adoptive Transfer | 1 | 2013 | 235 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2018 | 706 | 0.090 |
Why?
|
| Heart Defects, Congenital | 1 | 2024 | 1880 | 0.090 |
Why?
|
| Health Status | 1 | 2014 | 371 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 2094 | 0.090 |
Why?
|
| Risk | 1 | 2013 | 723 | 0.090 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 714 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 609 | 0.090 |
Why?
|
| Parents | 1 | 2018 | 1116 | 0.080 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 1277 | 0.080 |
Why?
|
| Thrombocytopenia | 2 | 2024 | 220 | 0.080 |
Why?
|
| Cell Line | 1 | 2014 | 2554 | 0.080 |
Why?
|
| Postoperative Complications | 2 | 2021 | 3113 | 0.080 |
Why?
|
| Aged | 2 | 2024 | 20829 | 0.070 |
Why?
|
| Graft vs Host Disease | 1 | 2014 | 688 | 0.070 |
Why?
|
| Pediatrics | 1 | 2018 | 1239 | 0.070 |
Why?
|
| Fatal Outcome | 2 | 2018 | 356 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2577 | 0.060 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2025 | 68 | 0.050 |
Why?
|
| Ribonuclease III | 1 | 2025 | 100 | 0.050 |
Why?
|
| Wnt Signaling Pathway | 1 | 2026 | 208 | 0.050 |
Why?
|
| Inosine | 1 | 2024 | 7 | 0.050 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2025 | 160 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1266 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2025 | 2010 | 0.050 |
Why?
|
| Hydroxamic Acids | 1 | 2024 | 60 | 0.050 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2024 | 88 | 0.050 |
Why?
|
| Kynurenine | 1 | 2023 | 24 | 0.050 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 23 | 0.050 |
Why?
|
| Consensus | 1 | 2025 | 520 | 0.050 |
Why?
|
| Tetrazoles | 1 | 2023 | 71 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 1 | 2025 | 639 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2026 | 1026 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 354 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2026 | 2289 | 0.040 |
Why?
|
| Hoarseness | 1 | 2020 | 13 | 0.040 |
Why?
|
| Hepatectomy | 1 | 2021 | 131 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2020 | 100 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2023 | 330 | 0.040 |
Why?
|
| Prednisone | 1 | 2020 | 237 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 355 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 211 | 0.040 |
Why?
|
| Respiratory Sounds | 1 | 2020 | 78 | 0.040 |
Why?
|
| Recurrence | 1 | 2023 | 1476 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2025 | 2553 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2022 | 573 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 708 | 0.040 |
Why?
|
| Corpus Callosum | 1 | 2019 | 105 | 0.040 |
Why?
|
| Risk Factors | 2 | 2026 | 10950 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2025 | 882 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 208 | 0.030 |
Why?
|
| Chromosome Banding | 1 | 2017 | 135 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 792 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2017 | 331 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2026 | 3679 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2017 | 125 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 655 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1440 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2017 | 318 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2016 | 123 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2026 | 3407 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 629 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 1069 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 387 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 2193 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 1237 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 1546 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 832 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 2016 | 225 | 0.020 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 861 | 0.020 |
Why?
|
| Chemokine CCL20 | 1 | 2012 | 17 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2012 | 57 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2012 | 85 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 254 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2012 | 358 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 902 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 2887 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 637 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 6402 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 1275 | 0.020 |
Why?
|
| Genomics | 1 | 2016 | 1617 | 0.020 |
Why?
|
| Cell Movement | 1 | 2012 | 875 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2016 | 3814 | 0.020 |
Why?
|
| Texas | 1 | 2014 | 3648 | 0.010 |
Why?
|